Verve Therapeutics, Inc. (NASDAQ:VERV) Holdings Raised by Stifel Financial Corp

Stifel Financial Corp increased its stake in Verve Therapeutics, Inc. (NASDAQ:VERV) by 14.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 131,406 shares of the company’s stock after purchasing an additional 16,842 shares during the quarter. Stifel Financial Corp owned approximately 0.16% of Verve Therapeutics worth $636,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Creative Planning acquired a new position in shares of Verve Therapeutics in the third quarter worth about $50,000. PFG Investments LLC acquired a new stake in Verve Therapeutics during the 3rd quarter valued at $53,000. Erste Asset Management GmbH purchased a new stake in shares of Verve Therapeutics in the third quarter valued at $56,000. Daiwa Securities Group Inc. boosted its position in shares of Verve Therapeutics by 89.8% in the second quarter. Daiwa Securities Group Inc. now owns 12,094 shares of the company’s stock worth $59,000 after buying an additional 5,723 shares during the period. Finally, Cornercap Investment Counsel Inc. grew its holdings in shares of Verve Therapeutics by 13.5% during the second quarter. Cornercap Investment Counsel Inc. now owns 14,956 shares of the company’s stock valued at $73,000 after buying an additional 1,778 shares in the last quarter. Institutional investors and hedge funds own 97.11% of the company’s stock.

Verve Therapeutics Price Performance

Shares of Verve Therapeutics stock opened at $5.77 on Thursday. The stock has a 50-day simple moving average of $5.81 and a 200-day simple moving average of $5.67. Verve Therapeutics, Inc. has a 52-week low of $4.30 and a 52-week high of $19.34. The firm has a market cap of $488.51 million, a price-to-earnings ratio of -2.35 and a beta of 1.71.

Verve Therapeutics (NASDAQ:VERV) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.11. The business had revenue of $6.87 million for the quarter, compared to the consensus estimate of $2.75 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. Verve Therapeutics’s revenue for the quarter was up 120.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.72) EPS. As a group, equities research analysts predict that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

VERV has been the subject of several research analyst reports. Canaccord Genuity Group increased their price objective on Verve Therapeutics from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. HC Wainwright decreased their price target on shares of Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Finally, Royal Bank of Canada lowered their price objective on shares of Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.